Pharma Companies in Flux Over Trump's 200% Tariff Move on Generics The US President Donald Trump's announcement to impose tariffs on generic medicines imported from India has sent shockwaves through the global pharma industry.
The plan, which escalates to 200% a year after August 2028, aims to "onshore" manufacturing and create jobs in the US.
However, beneath this rhetoric lies a complex web of implications that threaten not only India's $30 billion pharma industry but also the affordability of essential medicines for millions of Americans.